Core Insights - The demand for grape seed health products is increasing due to rising living standards and health awareness among consumers [1][16] - The market size of grape seed health products in China is projected to grow from 5 billion yuan in 2019 to 9 billion yuan by 2024, with a compound annual growth rate of 12% [1][16] - Technological advancements in extraction efficiency and purity are supporting the growth of the grape seed health product market [1][16] Industry Overview - Grape seed health products are derived from grape seeds and contain beneficial components such as vitamins, minerals, amino acids, and antioxidants, offering various health benefits [3][10] - The industry can be categorized by product form (tablets, capsules, liquid), efficacy (antioxidant, anti-aging), and usage scenarios (daily health, beauty, sports nutrition) [5][10] Market Dynamics - The grape seed health product market is experiencing rapid expansion due to the growth of e-commerce and diversified marketing channels [1][16] - The increase in grape production in China, from 13.16 million tons in 2015 to 16.17 million tons in 2023, is expected to provide ample raw materials for grape seed health products [12][14] Regulatory Environment - Recent policies in China aim to promote the integration of the food industry with health and wellness sectors, enhancing the market for functional foods and health products [6][9] Competitive Landscape - Major players in the grape seed health product market include well-known domestic brands such as汤臣倍健 (Tongrentang), 康恩贝 (Kang En Bei), and 九芝堂 (Jiu Zhi Tang), as well as international brands like Nature's Way and NOW Foods [18][19] - Companies are enhancing their competitiveness through improved production technologies and brand marketing strategies [18][19] Consumer Trends - There is a notable increase in consumer demand for high-quality grape seed health products, particularly among women and young adults aged 18 to 35, who represent 83.7% of the health supplement market [24][25] - Consumers are increasingly focused on product quality, efficacy, and safety, necessitating continuous improvement in product formulations [24][25] Future Outlook - The industry is expected to benefit from technological advancements that enhance product absorption and bioavailability [25][26] - The trend of online and offline integration in sales channels is becoming crucial for market growth, providing consumers with a more convenient shopping experience [26][27] - International expansion is a growing trend, with Chinese companies leveraging their resources and technology to compete in global markets [27]

Core Viewpoint - The credit rating report for Xianle Health Technology Co., Ltd. indicates a stable credit rating of AA- with a focus on the company's strong production capabilities and market position in the nutritional health food sector [3][6][11]. Company Overview - Xianle Health specializes in B-end business as a significant contract manufacturer of nutritional health foods, with a diverse product line including soft capsules, gummies, beverages, tablets, powders, and hard capsules [3][17]. - The company has established seven production bases and five R&D centers across China, Europe, and the United States, enhancing its manufacturing and research capabilities [5][17]. Financial Performance - In 2024, the company achieved total revenue of 42.11 billion yuan, representing a year-on-year growth of 17.56%, with a gross profit margin of 31.46% [5][22]. - Key financial metrics include total assets of 56.14 billion yuan and total liabilities of 16.19 billion yuan as of 2024 [3][22]. Market Position and Growth - The global nutritional health food market is projected to grow, with the Chinese market expected to reach 260.2 billion yuan in 2024, reflecting a compound annual growth rate of 6.3% from 2019 to 2024 [11][12]. - The company has seen a significant increase in overseas revenue, which accounted for 60.56% of total revenue by the end of 2024, driven by sales growth in the Americas [22]. Product and R&D Capabilities - The company has over 6,000 mature nutritional health food formulations and has received multiple health food registration certificates, indicating strong product development capabilities [17][16]. - R&D expenses increased by 13.98% in 2024, showcasing the company's commitment to innovation and product development [16]. Debt and Financial Stability - The company's debt structure is considered reasonable, with a strong ability to generate cash flow from operations, and a good EBITDA interest coverage ratio [6][22]. - The company issued 10.25 billion yuan in convertible bonds to fund expansion projects, with a portion of the funds redirected to supplement working capital [8][9]. Industry Environment - The nutritional health food industry is supported by government policies promoting health management and the "Healthy China" initiative, which is expected to drive market growth [12][11]. - New consumption trends, including online and cross-border sales channels, are emerging, with a notable increase in the online penetration rate of nutritional health products [13][14].

信用评级报告声明 除因本次评级事项本评级机构与评级对象构成委托关系外，本评级机构及评级从业人员与评级对象不存 在任何足以影响评级行为独立、客观、公正的关联关系。 本评级机构与评级从业人员已履行尽职调查义务，有充分理由保证所出具的评级报告遵循了真实、客观、 公正原则，但不对评级对象及其相关方提供或已正式对外公布信息的合法性、真实性、准确性和完整性 作任何保证。 本评级机构依据内部信用评级标准和工作程序对评级结果作出独立判断，不受任何组织或个人的影响。 仙乐健康科技股份有限公司相关 债券 2025 年跟踪评级报告 中鹏信评【2025】跟踪第【157】号 01 本评级报告观点仅为本评级机构对评级对象信用状况的个体意见，不作为购买、出售、持有任何证券的 建议。本评级机构不对任何机构或个人因使用本评级报告及评级结果而导致的任何损失负责。 本次评级结果自本评级报告所注明日期起生效，有效期为被评证券的存续期。同时，本评级机构已对受 评对象的跟踪评级事项做出了明确安排，并有权在被评证券存续期间变更信用评级。本评级机构提醒报 告使用者应及时登陆本公司网站关注被评证券信用评级的变化情况。 本评级报告版权归本评级机构所有，未经授权 ...

Investment Rating - The investment rating for the industry is "Increase" for key stocks such as Xianle Health and Tongrentang [6]. Core Insights - The health consumption trend is rising, with the nutrition and health product category maintaining rapid growth. The total sales for nutrition and health products during the 618 shopping festival in 2025 are projected to reach 14.3 billion yuan, a 55% increase from 9.2 billion yuan in 2024 [1]. - Emerging channels like instant retail are performing well, with Meituan reporting over a 200% year-on-year increase in orders for health supplements [1]. - Traditional categories are expanding steadily, with high-growth segments like anti-aging and liver protection showing significant sales growth [2]. - Leading brands such as Swisse and Tongrentang maintain their positions, while new brands are emerging with competitive pricing and niche market strategies [3]. Summary by Sections Industry Overview - The nutrition and health product sector is experiencing robust growth, driven by health-conscious consumer behavior and the rise of e-commerce and new retail channels [1]. Product Categories - Key categories with strong sales during the 618 festival include infant nutrition products, special medical foods, and fish oil. Anti-aging products are among the fastest-growing segments [2]. Brand Analysis - The top brands on platforms like Tmall and JD remain consistent, with Swisse and Tongrentang leading. New entrants are gaining traction by focusing on quality and cost-effectiveness [3]. Investment Recommendations - The report suggests focusing on companies with clear competitive advantages in the contract manufacturing segment, such as Xianle Health and Baihe Shares, and high-quality brand operators like H&H International Holdings and Tongrentang [4].

证券代码：300791 证券简称：仙乐健康 公告编码：2025-058 债券代码：123113 债券简称：仙乐转债 仙乐健康科技股份有限公司 2025 年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现增加、否决或变更议案的情形； 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、 会议召开情况 1、现场会议召开时间：2025 年 6 月 12 日（星期四）14:30 2、现场会议召开地点：汕头市龙湖区泰山路 83 号公司行政楼会议室 3、网络投票时间：2025 年 6 月 12 日 其中，通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 6 月 12 日 9:15-9:25，9:30-11:30 和 13:00-15:00； 通过深圳证券交易所互联网投票系统投票的具体时间为：2025 年 6 月 12 日 9:15-15:00 期间的任意时间。 6、会议的召集、召开与表决程序符合《中华人民共和国公司法》、《深 圳证券交易所创业板股票上市规则》、《深圳证券交易所上市公司自律监 ...

广东信达律师事务所 股东大会法律意见书 中国深圳福田区益田路 6001 号太平金融大厦 11 楼、12 楼 邮政编码：518038 11、12/F, TaiPingFiance Tower,Yitian Road 6001,Futian District, ShenZhen, P. R. China 电话(Tel.)：(0755) 88265288 传真(Fax.)：(0755)88265537 网址(Website)：https://www.sundiallawfirm.com 广东信达律师事务所 关于仙乐健康科技股份有限公司 2025年第二次临时股东大会的 法律意见书 本所律师依据《股东会规则》第六条的规定，按照中国律师行业公认的业务 标准、道德规范和勤勉尽责的精神，现出具法律意见如下： 一、关于本次股东大会的召集与召开程序 信达会字（2025）第191号 致：仙乐健康科技股份有限公司（下称"贵公司"） 广东信达律师事务所接受贵公司的委托，指派周蒴婷律师及刘品律师（下称 "本所律师"）参加了贵公司2025年第二次临时股东大会（下称"本次股东大会"）， 并进行了必要的验证工作。现根据《中华人民共和国公司法》 ...

保健品之新：新品类 悦己特征突出，美容养颜类高景气。颜值经济驱动下，美容养颜、身材管理、运动健身、护发固发此类 与"颜值经济"相关的功效品类遥遥领先，在抖音TOP20的商品中，占据超49%的市场份额，同时护肝、 润喉赛道增速亮眼，三高心血管健康、骨骼健康市场体量稳固。营养健康食品零食化趋势显著，年轻消 费者更倾向即食软糖、冲泡粉剂等形态，非蓝帽子产品接受度提升，功能性食品销量占比持续增长。抗 衰老赛道扩容加速，麦角硫因因超强抗氧化能力成为出圈爆点，跨境品牌充分受益。 保健品之新：新群体 消费群体年轻化与下沉化趋势明显，女性、Z世代及宠物主成为核心增量人群，其中31-40岁消费者占比 最高，24-30岁增速最快，下沉市场消费者占比提升，低线城市成为高潜用户。 中信建投（601066）发布研报称，国内保健品市场正经历结构性变革，渠道、品类与消费群体呈现显著 分化，新消费特征正在驱动行业价值重估。线上渠道凭借高渗透率与灵活性持续扩张，短视频、跨境电 商及私域平台成为增长引擎，而传统药店受政策与客流影响持续萎缩。消费群体年轻化与下沉化趋势明 显，女性、Z世代及宠物主成为核心增量人群。保健品公司通过跨境布局、产品创新及 ...

关于仙乐健康科技股份有限公司向不特定对象发行可转换 公司债券部分募投项目结项或调整建设投资规模后结项并 将节余募集资金永久补充流动资金的核查意见 招商证券股份有限公司（以下简称"招商证券"或"保荐机构"）作为仙乐 健康科技股份有限公司（以下简称"仙乐健康"或"公司"）向不特定对象发行 可转换公司债券的保荐机构及持续督导机构，根据《证券发行上市保荐业务管理 办法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律 监管指引第 2 号——创业板上市公司规范运作》及《上市公司监管指引第 2 号 ——上市公司募集资金管理和使用的监管要求》等相关法律法规和规范性文件的 要求，对公司向不特定对象发行可转换公司债券部分募投项目结项或调整建设投 资规模后结项并将节余募集资金永久补充流动资金的事项进行了审慎核查，核查 情况及核查意见如下： 一、募集资金基本情况 （一）实际募集资金金额和资金到账时间 经中国证券监督管理委员会《关于同意仙乐健康科技股份有限公司向不特定 对象发行可转换公司债券注册的批复》（证监许可[2021]927 号）同意注册，公 司向不特定对象发行可转换公司债券数量 10,248,929 张，募集 ...

| 证券代码：300791 | 证券简称：仙乐健康 | 公告编码：2025-056 | | --- | --- | --- | | 债券代码：123113 | 债券简称：仙乐转债 | | 仙乐健康科技股份有限公司 表了明确同意的意见。该事项尚需提交股东大会审议。现将有关情况公告如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意仙乐健康科技股份有限公司向不特定 对象发行可转换公司债券注册的批复》（证监许可〔2021〕927 号）核准，公司 于 2021 年 4 月 19 日向不特定对象以每张面值人民币 100 元的发行价格公开发行 10,248,929 张可转换公司债券，募集资金总额计人民币 102,489.29 万元，扣除保 荐费和承销费用共计人民币 872.54 万元后，公司实际收到上述可转换公司债券 的募集资金人民币 101,616.75 万元，扣除由公司支付的保荐费、审计及验资费、 律师费等其他发行费用合计人民币 275.89 万元后，实际募集资金净额为人民币 101,340.86 万元。上述募集资金于 2021 年 4 月 23 日全部到账，并经华兴会计师 事务所（特殊普通合伙）验证并出 ...

| 证券代码：300791 | 证券简称：仙乐健康 | 公告编码：2025-057 | | --- | --- | --- | | 证券代码：123113 | 证券简称：仙乐转债 | | 仙乐健康科技股份有限公司 关于召开 2025 年第二次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 仙乐健康科技股份有限公司（以下简称"公司"、"本公司"）定于 2025 年 6 月 12 日（星期四）召开 2025 年第二次临时股东大会，现将会议有关事项通知 如下： 一、本次股东大会召开的基本情况 1、股东大会届次：2025 年第二次临时股东大会。 2、会议召集人：公司第四届董事会。 3、会议召开的合法性、合规性情况：经公司第四届董事会第十次会议审议 并通过了《关于提请召开 2025 年第二次临时股东大会的议案》。召集程序符合有 关法律、行政法规、部门规章、规范性文件和公司章程的规定。 4、会议召开日期与时间： （1）现场会议召开时间：2025 年 6 月 12 日（星期四）14:30； （2）网络投票时间：2025 年 6 月 12 日 其中，通过深 ...